Biohaven anxiety treatment fails late-stage study, shares fall 16%Alzheimer’s disease, Business, Clinical Trials, Daily Activities, Obsessive-Compulsive Disorders, R&D, Shares, Spinocerebellar AtaxiaShares of Biohaven Pharmaceutical Holding Company Ltd. fell 16 percent after the company’s treatment for anxiety disorder failed to meet the main goal in a late-stage study. Read more February 10, 2020/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2020-02-10 08:05:072020-02-10 22:59:49Biohaven anxiety treatment fails late-stage study, shares fall 16%
